EMEA-001748-PIP02-18

Key facts

Active substance
arimoclomol citrate
Therapeutic area
Neurology
Decision number
P/0317/2018
PIP number
EMEA-001748-PIP02-18
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
  • Treatment of amyotrophic lateral sclerosis
  • Treatment of sporadic inclusion body myositis
Route(s) of administration
Oral use
Contact for public enquiries
Orphazyme A/S

Tel. +45 20727120
E-mail: alk@orphazyme.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating